



Medicine Supply Notification

MSN/2026/048

FemSeven Conti® (estradiol 50micrograms and levonorgestrel 7micrograms/24hours) transdermal patches

Tier 2 – medium impact*

Date of issue: 12/10/2026

Link: [Medicines Supply Tool](#)

Summary

- **FemSeven Conti®** (estradiol 50micrograms and levonorgestrel 7micrograms/24hours) transdermal patches are out of stock until late-November 2026.
- The following 24-hour transdermal patches remain available and can support increased demand:
 - Evorel Conti®** (estradiol 50micrograms/norethisterone 170micrograms)
 - Estradot Conti® 30/95** (estradiol 30micrograms/norethisterone 95micrograms)
 - Estradot Conti® 40/130** (estradiol 40micrograms/norethisterone 130micrograms)
- Alternative hormone replacement therapy (HRT) products remain available.

Actions Required

Prescribers should not initiate new patients on FemSeven Conti® patches until the supply issue has resolved.

Where patients have insufficient patches to last until the re-supply date, prescribers should:

- consider prescribing Evorel Conti® or Estradot Conti® patches, taking into account treatment history, ensuring that the patient is not intolerant to any of the excipients, and is counselled on the frequency of patch change;
- where the above options are not suitable, consider prescribing transdermal estradiol with an alternative progestogen separately, ensuring no intolerance of the excipients, and counselling is provided on dosing, administration, and importance of taking the progestogen correctly and consistently in women with an intact uterus (see Supporting Information); and
- advise patients who have been switched to an alternative product to report changes in symptom control or development of adverse effects.

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Supporting information

Clinical Information

Femseven Conti® contains a continuous combined combination of oestrogen and progestogen for continuous use.

Of the other continuous combined transdermal HRT preparations available, only one contains the same amount of estradiol as Femseven Conti®, and all contain a different progestogen of varying strengths (see table).

Presentation	Estradiol	Progestogen	Dose frequency
FemSeven Conti®	50 micrograms	Levonorgestrel (7 micrograms)	Once a week.
Alternative preparations			
Evorel Conti®	50 micrograms	Norethisterone (170 micrograms)	Twice a week
Estradot Conti® 30/95	30 micrograms	Norethisterone (95 micrograms)	Twice a week
Estradot Conti® 40/130	40 micrograms	Norethisterone (130 micrograms)	

When switching from a continuous combined regimen (such as FemSeven Conti®), the new regimen can be started at any point in the cycle.

The British Menopause Society (BMS) '[HRT preparations and equivalent alternatives](#)' tool suggests another option is transdermal estradiol delivery with an alternative progestogen by taking estrogen and progestogen separately. Women with an intact uterus require oestrogen **and** progestogen (for endometrial protection). If they are switched to a formulation where the progestogen is given separate to the oestrogen component, they should be counselled on the importance of taking the progestogen correctly and consistently.

Note on supply of other products

- Supply of Estradot® (estradiol) transdermal patches is limited, see [Serious Shortage Protocols](#) and [Medicine Supply Tool](#) for further information.
- Evorel® (estradiol 1mg/g transdermal gel; 500microgram per actuation) has recently become available, but is not yet included in the BMS tool, see [SmPC](#) for further information.

Links to further information

[SmPC – FemSeven Conti®](#)

[SmPC – Evorel Conti®](#)

[SmPC – Estradot Conti®](#)

[CKS: Menopause – Hormone replacement therapy](#)

[British Menopause Society - HRT preparations and equivalent alternatives](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.